{"id":55566,"date":"2025-05-03T14:10:26","date_gmt":"2025-05-03T11:10:26","guid":{"rendered":"https:\/\/saudishopper.com.sa\/en\/?p=55566"},"modified":"2026-03-28T07:46:01","modified_gmt":"2026-03-28T04:46:01","slug":"lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum","status":"publish","type":"post","link":"https:\/\/saudishopper.com.sa\/en\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\/","title":{"rendered":"Lilly reports first-quarter 2025 financial results and highlights pipeline momentum"},"content":{"rendered":"\n<ul class=\"wp-block-list\">\n<li><em>Revenue in Q1 2025 increased 45% to $12.73 billion driven by volume growth from Mounjaro and Zepbound<\/em><\/li>\n\n\n\n<li><em>Pipeline progress included positive Phase 3 trial results for orforglipron (small molecule oral GLP-1 agonist) in Type 2 diabetes in the first of seven obesity and diabetes Phase 3 trials<\/em><\/li>\n\n\n\n<li><em>Q1 2025 EPS increased 23% to $3.06 on a reported basis and increased 29% to $3.34 on a non-GAAP basis, both inclusive of $1.72 of acquired IPR&amp;D charges<\/em><\/li>\n\n\n\n<li><em>Revenue guidance reaffirmed to be between $58.0 billion and $61.0 billion<\/em><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>May 2025<\/strong>: Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;Lilly had a solid start to the year, with 45% year-over-year revenue growth driven by strong sales of Mounjaro and Zepbound,&#8221; said David A. Ricks, Lilly chair and CEO. &#8220;Our pipeline continued to deliver across key therapeutic areas, with product approvals in oncology and immunology, and the exciting success of our oral incretin, orforglipron, in the first of seven late-stage studies in diabetes and obesity. To support global demand for our newest medicines, we&#8217;re accelerating our manufacturing investments, as underscored by our recent announcement to build four new facilities.&#8221;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-results\">Financial Results<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td>$ in millions, except per share data<\/td><td colspan=\"5\">First-Quarter<\/td><\/tr><tr><td><\/td><td>2025<\/td><td><\/td><td>2024<\/td><td><\/td><td>% Change<\/td><\/tr><tr><td>Revenue<\/td><td>$ 12,728.5<\/td><td><\/td><td>$&nbsp;&nbsp; 8,768.0<\/td><td><\/td><td>45&nbsp;%<\/td><\/tr><tr><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td>Net income \u2013 Reported<\/td><td>2,759.3<\/td><td><\/td><td>2,242.9<\/td><td><\/td><td>23&nbsp;%<\/td><\/tr><tr><td>Earnings per share \u2013 Reported<\/td><td>3.06<\/td><td><\/td><td>2.48<\/td><td><\/td><td>23&nbsp;%<\/td><\/tr><tr><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td>Net income \u2013 Non-GAAP<\/td><td>3,004.4<\/td><td><\/td><td>2,335.3<\/td><td><\/td><td>29&nbsp;%<\/td><\/tr><tr><td>Earnings per share \u2013 Non-GAAP<\/td><td>3.34<\/td><td><\/td><td>2.58<\/td><td><\/td><td>29&nbsp;%<\/td><\/tr><tr><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">A discussion of the non-GAAP financial measures is included below under &#8220;Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited).&#8221;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-first-quarter-reported-results\">First-Quarter Reported Results<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">In Q1 2025, worldwide revenue was&nbsp;$12.73 billion, an increase of 45% compared with Q1 2024, driven by a 53% increase in volume, partially offset by a 6% decrease due to lower realized prices and a 2% unfavorable impact of foreign exchange rates. Key Products<sup>1<\/sup>&nbsp;revenue grew by&nbsp;$4.09 billion&nbsp;to&nbsp;$7.52 billion&nbsp;in Q1 2025, led by Mounjaro and Zepbound.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Revenue in the&nbsp;U.S.&nbsp;increased 49% to&nbsp;$8.49 billion, driven by a 57% increase in volume, partially offset by a 7% decrease due to lower realized prices. The increase in&nbsp;U.S.&nbsp;volume was driven by Zepbound and Mounjaro.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Revenue outside the&nbsp;U.S.&nbsp;increased 38% to&nbsp;$4.24 billion, driven by a 46% increase in volume. The volume increase outside the&nbsp;U.S.&nbsp;was driven primarily by Mounjaro and, to a lesser extent, Jardiance. Jardiance revenue included a one-time benefit of&nbsp;$370.0 million&nbsp;associated with an amendment to the company&#8217;s collaboration with&nbsp;Boehringer Ingelheim. Pursuant to the amendment, we and&nbsp;Boehringer Ingelheim&nbsp;adjusted commercialization responsibilities for Jardiance within certain markets.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Gross margin increased 48% to&nbsp;$10.50 billion&nbsp;in Q1 2025. Gross margin as a percent of revenue was 82.5%, an increase of 1.6 percentage points. The increase in gross margin percent was primarily driven by improved cost of production and favorable product mix, partially offset by lower realized prices.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In Q1 2025, research and development expenses increased 8% to&nbsp;$2.73 billion, or 21.5% of revenue, driven by continued investments in the company&#8217;s early and late-stage portfolio.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Marketing, selling and administrative expenses increased 26% to&nbsp;$2.47 billion&nbsp;in Q1 2025, primarily driven by promotional efforts supporting ongoing and future launches.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In Q1 2025, the company recognized acquired in-process research and development (IPR&amp;D) charges of&nbsp;$1.57 billion&nbsp;compared with&nbsp;$110.5 million&nbsp;in Q1 2024. The Q1 2025 charges primarily related to the acquisition of&nbsp;Scorpion Therapeutics, Inc.&#8217;s&nbsp;PI3K\u03b1 inhibitor program STX-478.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The effective tax rate was&nbsp;20.2% in Q1 2025 compared with 11.6% in Q1 2024, primarily driven by the unfavorable tax impact of a non-deductible acquired IPR&amp;D charge in Q1 2025. The 2025 and 2024 effective tax rates were impacted by discrete tax benefits in each period.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In Q1 2025, net income and earnings per share (EPS) were&nbsp;$2.76&nbsp;billion and&nbsp;$3.06, respectively, compared with net income of&nbsp;$2.24&nbsp;billion and EPS of&nbsp;$2.48&nbsp;in Q1 2024. EPS in Q1 2025 and Q1 2024 included acquired IPR&amp;D charges of&nbsp;$1.72&nbsp;and&nbsp;$0.10, respectively.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-first-quarter-non-gaap-measures\">First-Quarter Non-GAAP Measures<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">On a non-GAAP basis, Q1 2025 gross margin increased 47% to&nbsp;$10.63 billion. Gross margin as a percent of revenue was 83.5%, an increase of 1.0 percentage point. The increase in gross margin percent was primarily driven by improved cost of production and favorable product mix, partially offset by lower realized prices.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The effective tax rate on a non-GAAP basis was 20.2% in Q1 2025 compared with 11.9% in Q1 2024, primarily driven by the unfavorable tax impact of a non-deductible acquired IPR&amp;D charge in Q1 2025. The 2025 and 2024 effective tax rates were impacted by discrete tax benefits in each period.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">On a non-GAAP basis, Q1 2025 net income and EPS were&nbsp;$3.00 billion&nbsp;and&nbsp;$3.34, respectively, compared with net income of&nbsp;$2.34&nbsp;billion and EPS of&nbsp;$2.58&nbsp;in Q1 2024. Non-GAAP EPS in Q1 2025 and Q1 2024 included acquired IPR&amp;D charges of&nbsp;$1.72&nbsp;and&nbsp;$0.10, respectively.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For further detail on non-GAAP measures, see the reconciliation below as well as the &#8220;Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)&#8221; table later in this press release.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td>&nbsp;<\/td><td colspan=\"5\">First-Quarter<\/td><\/tr><tr><td><\/td><td>2025<\/td><td><\/td><td>2024<\/td><td><\/td><td>% Change<\/td><\/tr><tr><td><strong>Earnings per share (reported)<\/strong><\/td><td><strong>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.06<\/strong><\/td><td><\/td><td><strong>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.48<\/strong><\/td><td><\/td><td><strong>23&nbsp;%<\/strong><\/td><\/tr><tr><td>Amortization of intangible assets<\/td><td>.11<\/td><td><\/td><td>.12<\/td><td><\/td><td><\/td><\/tr><tr><td>Asset impairment, restructuring and other special charges<\/td><td>.03<\/td><td><\/td><td>\u2014<\/td><td><\/td><td><\/td><\/tr><tr><td>Net losses (gains) on investments in equity securities<\/td><td>.13<\/td><td><\/td><td>(.02)<\/td><td><\/td><td><\/td><\/tr><tr><td><strong>Earnings per share (non-GAAP)<\/strong><\/td><td><strong>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.34<\/strong><\/td><td><\/td><td><strong>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.58<\/strong><\/td><td><\/td><td><strong>29&nbsp;%<\/strong><\/td><\/tr><tr><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td>Acquired IPR&amp;D<\/td><td>1.72<\/td><td><\/td><td>.10<\/td><td><\/td><td>NM<\/td><\/tr><tr><td colspan=\"6\">Numbers may not add due to rounding<\/td><\/tr><tr><td colspan=\"6\">NM \u2013 not meaningful<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-selected-revenue-highlights\">Selected Revenue Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><em>(Dollars in millions)<\/em><\/td><td colspan=\"5\">First-Quarter<\/td><\/tr><tr><td><strong>Selected Products<\/strong><\/td><td>2025<\/td><td><\/td><td>2024<\/td><td><\/td><td>% Change<\/td><\/tr><tr><td>Mounjaro<\/td><td>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3,841.8<\/td><td><\/td><td>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,806.5<\/td><td><\/td><td>113&nbsp;%<\/td><\/tr><tr><td>Zepbound<\/td><td>2,311.9<\/td><td><\/td><td>517.4<\/td><td><\/td><td>NM<\/td><\/tr><tr><td>Verzenio<\/td><td>1,158.9<\/td><td><\/td><td>1,050.3<\/td><td><\/td><td>10&nbsp;%<\/td><\/tr><tr><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td><strong>Total Revenue<\/strong><\/td><td>12,728.5<\/td><td><\/td><td>8,768.0<\/td><td><\/td><td>45&nbsp;%<\/td><\/tr><tr><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td colspan=\"6\">NM \u2013 not meaningful<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mounjaro\">Mounjaro<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">For Q1 2025, worldwide Mounjaro revenue increased 113% to&nbsp;$3.84 billion.&nbsp;U.S.&nbsp;revenue was&nbsp;$2.66 billion, an increase of 75%, reflecting continued strong demand, partially offset by lower realized prices. Revenue outside the&nbsp;U.S.&nbsp;increased to&nbsp;$1.19 billion&nbsp;compared with&nbsp;$286.2 million&nbsp;in Q1 2024, primarily driven by volume growth, including entry into new markets, partially offset by lower realized prices.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-zepbound\">Zepbound<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">For Q1 2025,&nbsp;U.S.&nbsp;Zepbound revenue was&nbsp;$2.31 billion, compared with&nbsp;$517.4 million&nbsp;in Q1 2024, primarily driven by increased demand, partially offset by lower realized prices.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-verzenio\">Verzenio<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">For Q1 2025, worldwide Verzenio revenue increased 10% to&nbsp;$1.16 billion.&nbsp;U.S.&nbsp;revenue was&nbsp;$657.6 million, an increase of 3%, driven by higher realized prices. Increased demand was more than offset by wholesaler buying patterns and competitive dynamics. Revenue outside the&nbsp;U.S.&nbsp;was&nbsp;$501.3 million, an increase of 22%, primarily driven by volume growth, partially offset by the unfavorable impact of foreign exchange rates.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Lilly shared numerous updates recently on key regulatory, clinical, business development and other events, including:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td rowspan=\"2\"><strong>Regulatory<\/strong><\/td><td>Lilly&#8217;s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the&nbsp;European<br>Union&nbsp;for adults with relapsed or refractory chronic lymphocytic leukemia (CLL)<br>previously treated with a BTK inhibitor (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4417613-1&amp;h=2427280882&amp;u=https%3A%2F%2Flilly.mediaroom.com%2F2025-02-28-Lillys-Jaypirca-pirtobrutinib-recommended-by-CHMP-for-approval-in-the-European-Union-for-adults-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-CLL-previously-treated-with-a-BTK-inhibitor&amp;a=announcement\" target=\"_blank\" rel=\"noreferrer noopener\">announcement<\/a>). Jaypirca was approved in<br>the EU subsequent to the positive CHMP opinion.<\/td><\/tr><tr><td>Lilly&#8217;s statement about the CHMP opinion issued for donanemab (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4417613-1&amp;h=3065549810&amp;u=https%3A%2F%2Finvestor.lilly.com%2Fnews-releases%2Fnews-release-details%2Flillys-statement-about-chmp-opinion-issued-donanemab&amp;a=announcement\" target=\"_blank\" rel=\"noreferrer noopener\">announcement<\/a>).<\/td><\/tr><tr><td rowspan=\"5\"><strong>Clinical<\/strong><\/td><td>Lilly&#8217;s oral GLP-1, orforglipron, demonstrated statistically significant efficacy results<br>and a safety profile consistent with injectable GLP-1 medicines in successful Phase<br>3 trial (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4417613-1&amp;h=4177233913&amp;u=https%3A%2F%2Finvestor.lilly.com%2Fnews-releases%2Fnews-release-details%2Flillys-oral-glp-1-orforglipron-demonstrated-statistically&amp;a=announcement\" target=\"_blank\" rel=\"noreferrer noopener\">announcement<\/a>).<\/td><\/tr><tr><td>Lilly&#8217;s lepodisiran reduced levels of genetically inherited heart disease risk factor,<br>lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with<br>elevated levels (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4417613-1&amp;h=1189061243&amp;u=https%3A%2F%2Flilly.mediaroom.com%2F2025-03-30-Lillys-lepodisiran-reduced-levels-of-genetically-inherited-heart-disease-risk-factor%2C-lipoprotein-a-%2C-by-nearly-94-from-baseline-at-the-highest-tested-dose-in-adults-with-elevated-levels&amp;a=announcement\" target=\"_blank\" rel=\"noreferrer noopener\">announcement<\/a>).<\/td><\/tr><tr><td>Lilly&#8217;s baricitinib delivered high rates of hair regrowth for adolescents with severe<br>alopecia areata in Phase 3 BRAVE-AA-PEDS study (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4417613-1&amp;h=2071767322&amp;u=https%3A%2F%2Flilly.mediaroom.com%2F2025-03-08-Lillys-baricitinib-delivered-high-rates-of-hair-regrowth-for-adolescents-with-severe-alopecia-areata-in-Phase-3-BRAVE-AA-PEDS-study&amp;a=announcement\" target=\"_blank\" rel=\"noreferrer noopener\">announcement<\/a>).<\/td><\/tr><tr><td>Lilly&#8217;s EBGLYSS\u00ae (lebrikizumab-lbkz) single monthly maintenance injection<br>achieved completely clear skin at three years in half of patients with moderate-to-<br>severe atopic dermatitis (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4417613-1&amp;h=140582229&amp;u=https%3A%2F%2Flilly.mediaroom.com%2F2025-03-07-Lillys-EBGLYSS-R-lebrikizumab-lbkz-single-monthly-maintenance-injection-achieved-completely-clear-skin-at-three-years-in-half-of-patients-with-moderate-to-severe-atopic-dermatitis&amp;a=announcement\" target=\"_blank\" rel=\"noreferrer noopener\">announcement<\/a>).<\/td><\/tr><tr><td>Most patients on Lilly&#8217;s Omvoh\u00ae (mirikizumab-mrkz) for Crohn&#8217;s disease achieved<br>sustained clinical remission and endoscopic response at two years<br>(<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4417613-1&amp;h=2089450675&amp;u=https%3A%2F%2Flilly.mediaroom.com%2F2025-02-07-Most-patients-on-Lillys-Omvoh-R-mirikizumab-mrkz-for-Crohns-disease-achieved-sustained-clinical-remission-and-endoscopic-response-at-two-years&amp;a=announcement\" target=\"_blank\" rel=\"noreferrer noopener\">announcement<\/a>).<\/td><\/tr><tr><td rowspan=\"3\"><strong>Other<\/strong><\/td><td>LillyDirect platform expands to facilitate access to Alzheimer&#8217;s disease care<br>(<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4417613-1&amp;h=9593754&amp;u=https%3A%2F%2Finvestor.lilly.com%2Fnews-releases%2Fnews-release-details%2Flillydirect-platform-expands-facilitate-access-alzheimers&amp;a=announcement\" target=\"_blank\" rel=\"noreferrer noopener\">announcement<\/a>).<\/td><\/tr><tr><td>Lilly plans to more than double&nbsp;U.S.&nbsp;manufacturing investment since 2020<br>exceeding&nbsp;$50 billion&nbsp;(<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4417613-1&amp;h=2314660706&amp;u=https%3A%2F%2Flilly.mediaroom.com%2F2025-02-26-Lilly-plans-to-more-than-double-U-S-manufacturing-investment-since-2020-exceeding-50-billion&amp;a=announcement\" target=\"_blank\" rel=\"noreferrer noopener\">announcement<\/a>).<\/td><\/tr><tr><td>Lilly launches additional Zepbound vial doses and offers new savings for self-pay<br>patients (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4417613-1&amp;h=1653864238&amp;u=https%3A%2F%2Flilly.mediaroom.com%2F2025-02-25-Lilly-launches-additional-Zepbound-vial-doses-and-offers-new-savings-for-self-pay-patients&amp;a=announcement\" target=\"_blank\" rel=\"noreferrer noopener\">announcement<\/a>).<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">For information on important public announcements, visit the news section of Lilly&#8217;s website.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-2025-financial-guidance\">2025 Financial Guidance<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The company updated certain elements of its 2025 financial guidance to reflect the impact of the Q1 2025 acquired IPR&amp;D charges.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The company reaffirms its previous 2025 revenue guidance and expects it to be between&nbsp;$58.0 billion&nbsp;and&nbsp;$61.0 billion.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The performance margin<sup>2<\/sup>&nbsp;is still expected to be in the range of 40.5% and 42.5% on a reported basis and 41.5% and 43.5% on a non-GAAP basis.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Other income (expense) on a reported basis is now expected to be expense in the range of&nbsp;$850 million&nbsp;to&nbsp;$750 million&nbsp;due to net losses on investments in equity securities and is still expected to be expense in the range of&nbsp;$700 million&nbsp;to&nbsp;$600 million&nbsp;on a non-GAAP basis.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The 2025 estimated effective tax rate increased from approximately 16% to 17% on both a reported and non-GAAP basis, driven by the tax impact of the non-deductible acquired IPR&amp;D charge incurred in Q1 2025.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Guidance for EPS for 2025 decreased to the range of&nbsp;$20.17&nbsp;to&nbsp;$21.67&nbsp;on a reported basis, driven by the acquired IPR&amp;D charges and net losses on investments in equity securities and&nbsp;$20.78&nbsp;to&nbsp;$22.28&nbsp;on a non-GAAP basis, driven by the acquired IPR&amp;D charges. The company&#8217;s updated 2025 financial guidance reflects adjustments shown in the reconciliation table below.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>&nbsp;<\/strong><\/td><td><strong>2025<\/strong> <strong>Guidance<\/strong><strong><\/strong><\/td><\/tr><tr><td><strong>Earnings per share (reported)<\/strong><\/td><td><strong>$20.17&nbsp;to&nbsp;$21.67<\/strong><\/td><\/tr><tr><td>Amortization of intangible assets<\/td><td>.44<\/td><\/tr><tr><td>Asset impairment, restructuring, and other special charges<\/td><td>.03<\/td><\/tr><tr><td>Net losses on investments in equity securities<\/td><td>.13<\/td><\/tr><tr><td><strong>Earnings per share (non-GAAP)<\/strong><\/td><td><strong>$20.78&nbsp;to&nbsp;$22.28<\/strong><\/td><\/tr><tr><td colspan=\"2\">Numbers may not add due to rounding<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The following table summarizes the company&#8217;s updated 2025 financial guidance:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td>&nbsp;<\/td><td>&nbsp;<\/td><td>&nbsp;<\/td><td><strong>Prior<\/strong><\/td><td><strong>Updated<sup>(1) (2) (3)<\/sup><\/strong><\/td><\/tr><tr><td>Revenue<\/td><td><\/td><td><\/td><td>$58.0&nbsp;to&nbsp;$61.0 billion<\/td><td>Unchanged<\/td><\/tr><tr><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td>Performance Margin<sup>(4)<\/sup><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td>(reported)<\/td><td><\/td><td><\/td><td>40.5% to 42.5%<\/td><td>Unchanged<\/td><\/tr><tr><td>(non-GAAP)<\/td><td><\/td><td><\/td><td>41.5% to 43.5%<\/td><td>Unchanged<\/td><\/tr><tr><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td>Other Income\/(Expense) (reported)<\/td><td><\/td><td><\/td><td>($700) to&nbsp;($600) million<\/td><td>($850) to&nbsp;($750) million<\/td><\/tr><tr><td>Other Income\/(Expense) (non-GAAP)<\/td><td><\/td><td><\/td><td>($700) to&nbsp;($600) million<\/td><td>Unchanged<\/td><\/tr><tr><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td>Tax Rate<\/td><td><\/td><td><\/td><td>Approx. 16%<\/td><td>Approx. 17%<\/td><\/tr><tr><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td>Earnings per Share (reported)<\/td><td><\/td><td><\/td><td>$22.05&nbsp;to&nbsp;$23.55<\/td><td>$20.17&nbsp;to&nbsp;$21.67<\/td><\/tr><tr><td>Earnings per Share (non-GAAP)<\/td><td><\/td><td><\/td><td>$22.50&nbsp;to&nbsp;$24.00<\/td><td>$20.78&nbsp;to&nbsp;$22.28<\/td><\/tr><tr><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td colspan=\"5\"><sup>(1)<\/sup>&nbsp;Non-GAAP guidance reflects adjustments presented in the earnings per share reconciliation table above.<\/td><\/tr><tr><td colspan=\"5\"><sup>(2)<\/sup>&nbsp;Guidance includes acquired IPR&amp;D charges through Q1 2025 of&nbsp;$1.57 billion&nbsp;or&nbsp;$1.72&nbsp;on a per share basis. Guidance does not include acquired IPR&amp;D either incurred, or expected to be incurred, after Q1 2025.<\/td><\/tr><tr><td colspan=\"5\"><sup>(3)<\/sup>&nbsp;This guidance is based on the existing tariff and trade environment as of&nbsp;May 1, 2025, and does not reflect any policy shifts, including pharmaceutical sector tariffs, that could impact business.<\/td><\/tr><tr><td colspan=\"5\"><sup>(4)<\/sup>&nbsp;The Company defines performance margin as gross margin less&nbsp;R&amp;D, Marketing, Selling, and Administrative, and Asset Impairment, Restructuring and Other Charges divided by revenue.<\/td><\/tr><\/tbody><\/table><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>May 2025: Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025. &#8220;Lilly had a solid start to the year, with 45% year-over-year revenue growth driven by strong sales of Mounjaro and Zepbound,&#8221; said David A. Ricks, Lilly chair and CEO. &#8220;Our pipeline continued to deliver across key therapeutic [&hellip;]<\/p>\n","protected":false},"author":16,"featured_media":55567,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_meta-robots-noindex":"","_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","_pr_autopilot_social_copy":"","_yoast_wpseo_opengraph_title":"","_yoast_wpseo_opengraph_description":"","_yoast_wpseo_opengraph_image":"","_yoast_wpseo_opengraph_image_id":0,"_yoast_wpseo_twitter_title":"","_yoast_wpseo_twitter_description":"","_yoast_wpseo_twitter_image":"","_yoast_wpseo_twitter_image_id":0,"_yoast_wpseo_primary_category":24,"_extra_hide_author_box":"","_extra_featured_post":"","_partner_post_id":0,"footnotes":""},"categories":[24,72],"tags":[],"class_list":["post-55566","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-economy","category-health-tech","et-has-post-format-content","et_post_format-et-post-format-standard"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Q1 2025 financial results - Pipeline momentum | Saudi Shopper<\/title>\n<meta name=\"description\" content=\"Q1 2025 financial results: Lilly reports 45% revenue growth to $12.73B, strong pipeline momentum, and reaffirmed guidance for 2025.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/saudishopper.com.sa\/en\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Q1 2025 financial results - Pipeline momentum | Saudi Shopper\" \/>\n<meta property=\"og:description\" content=\"Q1 2025 financial results: Lilly reports 45% revenue growth to $12.73B, strong pipeline momentum, and reaffirmed guidance for 2025.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/saudishopper.com.sa\/en\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\/\" \/>\n<meta property=\"og:site_name\" content=\"Saudishopper\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaudiShopper\" \/>\n<meta property=\"article:author\" content=\"https:\/\/www.facebook.com\/zamil\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-03T11:10:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-28T04:46:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/saudishopper.com.sa\/en\/wp-content\/uploads\/2025\/05\/Lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum_ssict_1200_800.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Zamil Safwan\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@zsafwan\" \/>\n<meta name=\"twitter:site\" content=\"@ssict\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Zamil Safwan\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\\\/\"},\"author\":{\"name\":\"Zamil Safwan\",\"@id\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/#\\\/schema\\\/person\\\/8351552105da6d5a684fb7e010f12047\"},\"headline\":\"Lilly reports first-quarter 2025 financial results and highlights pipeline momentum\",\"datePublished\":\"2025-05-03T11:10:26+00:00\",\"dateModified\":\"2026-03-28T04:46:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\\\/\"},\"wordCount\":1784,\"publisher\":{\"@id\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum_ssict_1200_800.webp\",\"articleSection\":[\"Economy &amp; Business\",\"Health &amp; Technology\"],\"inLanguage\":\"en-US\",\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\\\/\",\"url\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\\\/\",\"name\":\"Q1 2025 financial results - Pipeline momentum | Saudi Shopper\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum_ssict_1200_800.webp\",\"datePublished\":\"2025-05-03T11:10:26+00:00\",\"dateModified\":\"2026-03-28T04:46:01+00:00\",\"description\":\"Q1 2025 financial results: Lilly reports 45% revenue growth to $12.73B, strong pipeline momentum, and reaffirmed guidance for 2025.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\\\/#primaryimage\",\"url\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum_ssict_1200_800.webp\",\"contentUrl\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum_ssict_1200_800.webp\",\"width\":1200,\"height\":800,\"caption\":\"Lilly reports first-quarter 2025 financial results and highlights pipeline momentum_ssict_1200_800\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lilly reports first-quarter 2025 financial results and highlights pipeline momentum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/\",\"name\":\"Saudishopper\",\"description\":\"Saudi ICT Shopper News\",\"publisher\":{\"@id\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/#organization\",\"name\":\"Saudi ICT News\",\"alternateName\":\"Saudi ICT Shopper News\",\"url\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/wp-content\\\/uploads\\\/2020\\\/08\\\/SSTrans.png\",\"contentUrl\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/wp-content\\\/uploads\\\/2020\\\/08\\\/SSTrans.png\",\"width\":423,\"height\":165,\"caption\":\"Saudi ICT News\"},\"image\":{\"@id\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/SaudiShopper\",\"https:\\\/\\\/x.com\\\/ssict\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/#\\\/schema\\\/person\\\/8351552105da6d5a684fb7e010f12047\",\"name\":\"Zamil Safwan\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a483a8920db50e1d6142462856d7925f4a9543091c79df709d1380ea7fbef8ec?s=96&d=https%3A%2F%2Fsaudishopper.com.sa%2Fen%2Fwp-content%2Fuploads%2F2020%2F12%2Fcropped-ss-icon--150x150.png&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a483a8920db50e1d6142462856d7925f4a9543091c79df709d1380ea7fbef8ec?s=96&d=https%3A%2F%2Fsaudishopper.com.sa%2Fen%2Fwp-content%2Fuploads%2F2020%2F12%2Fcropped-ss-icon--150x150.png&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a483a8920db50e1d6142462856d7925f4a9543091c79df709d1380ea7fbef8ec?s=96&d=https%3A%2F%2Fsaudishopper.com.sa%2Fen%2Fwp-content%2Fuploads%2F2020%2F12%2Fcropped-ss-icon--150x150.png&r=g\",\"caption\":\"Zamil Safwan\"},\"description\":\"An experienced technologist with expertise spanning Digital Transformation, E-commerce, Start-ups, and Fintech. Zamil offers insightful analysis on the convergence of finance and technology in the evolving digital landscape.\",\"sameAs\":[\"https:\\\/\\\/zsafwan.net\",\"https:\\\/\\\/www.facebook.com\\\/zamil\",\"https:\\\/\\\/x.com\\\/@zsafwan\"],\"url\":\"https:\\\/\\\/saudishopper.com.sa\\\/en\\\/author\\\/zamil\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Q1 2025 financial results - Pipeline momentum | Saudi Shopper","description":"Q1 2025 financial results: Lilly reports 45% revenue growth to $12.73B, strong pipeline momentum, and reaffirmed guidance for 2025.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/saudishopper.com.sa\/en\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\/","og_locale":"en_US","og_type":"article","og_title":"Q1 2025 financial results - Pipeline momentum | Saudi Shopper","og_description":"Q1 2025 financial results: Lilly reports 45% revenue growth to $12.73B, strong pipeline momentum, and reaffirmed guidance for 2025.","og_url":"https:\/\/saudishopper.com.sa\/en\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\/","og_site_name":"Saudishopper","article_publisher":"https:\/\/www.facebook.com\/SaudiShopper","article_author":"https:\/\/www.facebook.com\/zamil","article_published_time":"2025-05-03T11:10:26+00:00","article_modified_time":"2026-03-28T04:46:01+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/saudishopper.com.sa\/en\/wp-content\/uploads\/2025\/05\/Lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum_ssict_1200_800.webp","type":"image\/webp"}],"author":"Zamil Safwan","twitter_card":"summary_large_image","twitter_creator":"@zsafwan","twitter_site":"@ssict","twitter_misc":{"Written by":"Zamil Safwan","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/saudishopper.com.sa\/en\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\/#article","isPartOf":{"@id":"https:\/\/saudishopper.com.sa\/en\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\/"},"author":{"name":"Zamil Safwan","@id":"https:\/\/saudishopper.com.sa\/en\/#\/schema\/person\/8351552105da6d5a684fb7e010f12047"},"headline":"Lilly reports first-quarter 2025 financial results and highlights pipeline momentum","datePublished":"2025-05-03T11:10:26+00:00","dateModified":"2026-03-28T04:46:01+00:00","mainEntityOfPage":{"@id":"https:\/\/saudishopper.com.sa\/en\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\/"},"wordCount":1784,"publisher":{"@id":"https:\/\/saudishopper.com.sa\/en\/#organization"},"image":{"@id":"https:\/\/saudishopper.com.sa\/en\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\/#primaryimage"},"thumbnailUrl":"https:\/\/saudishopper.com.sa\/en\/wp-content\/uploads\/2025\/05\/Lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum_ssict_1200_800.webp","articleSection":["Economy &amp; Business","Health &amp; Technology"],"inLanguage":"en-US","copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/saudishopper.com.sa\/en\/#organization"}},{"@type":"WebPage","@id":"https:\/\/saudishopper.com.sa\/en\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\/","url":"https:\/\/saudishopper.com.sa\/en\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\/","name":"Q1 2025 financial results - Pipeline momentum | Saudi Shopper","isPartOf":{"@id":"https:\/\/saudishopper.com.sa\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/saudishopper.com.sa\/en\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\/#primaryimage"},"image":{"@id":"https:\/\/saudishopper.com.sa\/en\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\/#primaryimage"},"thumbnailUrl":"https:\/\/saudishopper.com.sa\/en\/wp-content\/uploads\/2025\/05\/Lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum_ssict_1200_800.webp","datePublished":"2025-05-03T11:10:26+00:00","dateModified":"2026-03-28T04:46:01+00:00","description":"Q1 2025 financial results: Lilly reports 45% revenue growth to $12.73B, strong pipeline momentum, and reaffirmed guidance for 2025.","breadcrumb":{"@id":"https:\/\/saudishopper.com.sa\/en\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/saudishopper.com.sa\/en\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/saudishopper.com.sa\/en\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\/#primaryimage","url":"https:\/\/saudishopper.com.sa\/en\/wp-content\/uploads\/2025\/05\/Lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum_ssict_1200_800.webp","contentUrl":"https:\/\/saudishopper.com.sa\/en\/wp-content\/uploads\/2025\/05\/Lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum_ssict_1200_800.webp","width":1200,"height":800,"caption":"Lilly reports first-quarter 2025 financial results and highlights pipeline momentum_ssict_1200_800"},{"@type":"BreadcrumbList","@id":"https:\/\/saudishopper.com.sa\/en\/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/saudishopper.com.sa\/en\/"},{"@type":"ListItem","position":2,"name":"Lilly reports first-quarter 2025 financial results and highlights pipeline momentum"}]},{"@type":"WebSite","@id":"https:\/\/saudishopper.com.sa\/en\/#website","url":"https:\/\/saudishopper.com.sa\/en\/","name":"Saudishopper","description":"Saudi ICT Shopper News","publisher":{"@id":"https:\/\/saudishopper.com.sa\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/saudishopper.com.sa\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/saudishopper.com.sa\/en\/#organization","name":"Saudi ICT News","alternateName":"Saudi ICT Shopper News","url":"https:\/\/saudishopper.com.sa\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/saudishopper.com.sa\/en\/#\/schema\/logo\/image\/","url":"https:\/\/saudishopper.com.sa\/en\/wp-content\/uploads\/2020\/08\/SSTrans.png","contentUrl":"https:\/\/saudishopper.com.sa\/en\/wp-content\/uploads\/2020\/08\/SSTrans.png","width":423,"height":165,"caption":"Saudi ICT News"},"image":{"@id":"https:\/\/saudishopper.com.sa\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaudiShopper","https:\/\/x.com\/ssict"]},{"@type":"Person","@id":"https:\/\/saudishopper.com.sa\/en\/#\/schema\/person\/8351552105da6d5a684fb7e010f12047","name":"Zamil Safwan","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a483a8920db50e1d6142462856d7925f4a9543091c79df709d1380ea7fbef8ec?s=96&d=https%3A%2F%2Fsaudishopper.com.sa%2Fen%2Fwp-content%2Fuploads%2F2020%2F12%2Fcropped-ss-icon--150x150.png&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a483a8920db50e1d6142462856d7925f4a9543091c79df709d1380ea7fbef8ec?s=96&d=https%3A%2F%2Fsaudishopper.com.sa%2Fen%2Fwp-content%2Fuploads%2F2020%2F12%2Fcropped-ss-icon--150x150.png&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a483a8920db50e1d6142462856d7925f4a9543091c79df709d1380ea7fbef8ec?s=96&d=https%3A%2F%2Fsaudishopper.com.sa%2Fen%2Fwp-content%2Fuploads%2F2020%2F12%2Fcropped-ss-icon--150x150.png&r=g","caption":"Zamil Safwan"},"description":"An experienced technologist with expertise spanning Digital Transformation, E-commerce, Start-ups, and Fintech. Zamil offers insightful analysis on the convergence of finance and technology in the evolving digital landscape.","sameAs":["https:\/\/zsafwan.net","https:\/\/www.facebook.com\/zamil","https:\/\/x.com\/@zsafwan"],"url":"https:\/\/saudishopper.com.sa\/en\/author\/zamil\/"}]}},"_links":{"self":[{"href":"https:\/\/saudishopper.com.sa\/en\/wp-json\/wp\/v2\/posts\/55566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/saudishopper.com.sa\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/saudishopper.com.sa\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/saudishopper.com.sa\/en\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/saudishopper.com.sa\/en\/wp-json\/wp\/v2\/comments?post=55566"}],"version-history":[{"count":1,"href":"https:\/\/saudishopper.com.sa\/en\/wp-json\/wp\/v2\/posts\/55566\/revisions"}],"predecessor-version":[{"id":76303,"href":"https:\/\/saudishopper.com.sa\/en\/wp-json\/wp\/v2\/posts\/55566\/revisions\/76303"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/saudishopper.com.sa\/en\/wp-json\/wp\/v2\/media\/55567"}],"wp:attachment":[{"href":"https:\/\/saudishopper.com.sa\/en\/wp-json\/wp\/v2\/media?parent=55566"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/saudishopper.com.sa\/en\/wp-json\/wp\/v2\/categories?post=55566"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/saudishopper.com.sa\/en\/wp-json\/wp\/v2\/tags?post=55566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}